Price of childhood vaccine to drop by 30%
GAVI to reach millions of children with life-saving vaccine through partnership with Indian manufacturer
18 APRIL 2013 — The cost of immunizing millions of the world’s most vulnerable children against five deadly and debilitating diseases is set to fall, thanks to a supply agreement between Biological E Ltd of India and PMNCH member GAVI Alliance to reduce the cost of the pentavalent vaccine by one third. The five-in-one shot will be available to GAVI for just $1.19 per dose, compared to the 2012 weighted average price of $2.17. This new, more cost-effective price provides the opportunity for the GAVI Alliance to pay up to US$ 150 million less over the next four years compared with using lowest cost alternative suppliers.
Demand for pentavalent vaccine has been strong, with 70 of the 73 GAVI-eligible countries having already introduced it, and the three remaining countries – Somalia, Indonesia, and South Sudan – approved to do so. UNICEF, an Alliance partner, managed the tender process for GAVI, which saw agreements made with Biological E, Crucell, GlaxoSmithKline, Serum Institute of India and new pentavalent supplier, LG Life Sciences of the Republic of Korea.
The GAVI Alliance was created in 2000 to accelerate the introduction of new vaccines so that all children, no matter where they live, have the same access to this life-saving technology. National governments, donors and vaccine suppliers must all play their part to ensure infants in the poorest countries are protected. The partnership aggregates donor funding, pools demand from countries, and works with suppliers to deliver lower and more accessible pricing. This reduces risk to supplies, enabling all partners to benefit and, most importantly, ensuring that the world can urgently reach all children with the vaccines they need.